US00D934884S

(12) **United States Design Patent**
Bergenstal et al.

(10) **Patent No.: US D934,884 S**
(45) **Date of Patent: ** Nov. 2, 2021**

(54) **DISPLAY SCREEN WITH GRAPHICAL USER INTERFACE**

(71) Applicant: **HealthPartners Institute**, Bloomington, MN (US)

(72) Inventors: **Richard Mauritz Bergenstal**, Plymouth, MN (US); **Gregg Daniel Simonson**, Bloomington, MN (US); **Deborah Michelle Mullen**, Chattanooga, TN (US)

(73) Assignee: **HealthPartners Institute**, Bloomington, MN (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/690,827**

(22) Filed: **May 10, 2019**

(51) **LOC (13) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/485**

(58) **Field of Classification Search**
USPC D14/485–495
CPC G06F 19/34; G06F 19/3418; G06F 3/048; G06F 3/04847; G06F 1/1692; H04N 1/00424
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,559,868	B2		5/2003	Alexander et al.
D519,517	S		4/2006	Reynolds et al.
D525,264	S		7/2006	Chotai et al.
D531,637	S	*	11/2006	Chotai D14/486
D573,601	S		7/2008	Gregov et al.
D589,976	S		4/2009	Hosokawa et al.
D630,648	S		1/2011	Tokunaga et al.
D630,649	S		1/2011	Tokunaga et al.
D632,699	S		2/2011	Judy et al.
D633,514	S		3/2011	Tokunaga et al.
8,041,714	B2		10/2011	Aymeloglu et al.
D652,048	S		1/2012	Joseph

(Continued)

OTHER PUBLICATIONS

"AGP Reports." AGP-Ambulatory Glucose Profile, published Oct. 20, 2018 (Retrieved from the Internet Nov. 2, 2020). Internet URL: <https://web.archive.org/web/20181020074747/http://www.agpreport.org/agp/agpreports> (Year: 2018).*

(Continued)

Primary Examiner — Rachel A. Voorhies
(74) *Attorney, Agent, or Firm* — Merchant & Gould P.C.

(57) **CLAIM**

The ornamental design for a display screen with graphical user interface, as shown and described.

DESCRIPTION

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. **1** is a front view of a first embodiment of the display screen with graphical user interface, showing a color image; and,

FIG. **2** is a front view of a second embodiment thereof.

Except as indicated herein, the black dashed broken lines and dot-dot broken lines show portions of the display screen with graphical user interface that form no part of the claimed design. The dot-dash lines represent the display screen and also represent a boundary of the claimed design, and form no part of the claimed design.

The blue dashed broken lines representing 5% and 95% in the Ambulatory Glucose Profile region of FIG. **1** are part of the claimed design.

1 Claim, 2 Drawing Sheets

(1 of 2 Drawing Sheet(s) Filed in Color)



(56) **References Cited**

U.S. PATENT DOCUMENTS

D652,052	S		1/2012	Judy et al.	
8,133,178	B2		3/2012	Brauker	
D661,313	S		6/2012	Nenoki	
D667,417	S		9/2012	Long et al.	
D674,404	S		1/2013	Pearcy et al.	
D674,812	S		1/2013	Joseph	
D681,651	S		5/2013	Fletcher et al.	
D684,172	S		6/2013	Rytt et al.	
D685,810	S		7/2013	Way et al.	
D690,309	S		9/2013	Wenz et al.	
D692,911	S		11/2013	Pearcy et al.	
D694,252	S	*	11/2013	Helm	D14/485
D694,253	S	*	11/2013	Helm	D14/485
D700,616	S	*	3/2014	Chao	D14/485
D709,082	S		7/2014	Meegan et al.	
D709,518	S		7/2014	Meegan et al.	
D710,373	S		8/2014	Meegan et al.	
D714,327	S	*	9/2014	Wood	D14/485
D717,328	S		11/2014	Lin	
D717,331	S		11/2014	Lin	
D740,847	S	*	10/2015	Yampolskiy	D14/486
D756,371	S	*	5/2016	Bertnick	D14/485
D756,372	S	*	5/2016	Bertnick	D14/485
D757,071	S		5/2016	Kouvas et al.	
D759,073	S		6/2016	Winklevoss	
D773,478	S	*	12/2016	Wesley	D14/485
D774,058	S		12/2016	Dias et al.	
D775,144	S		12/2016	Vazquez	
D778,933	S	*	2/2017	Hotchkiss	D14/486
D780,199	S		2/2017	Croan	
D785,008	S		4/2017	Lim et al.	
D789,398	S	*	6/2017	Akana	D14/486
D800,757	S	*	10/2017	Mullen	D14/486
D802,001	S		11/2017	Javed et al.	
D804,496	S	*	12/2017	Wahila	D14/485
D808,982	S	*	1/2018	Kavanagh	D14/485
D809,545	S	*	2/2018	Ban	D14/486
D810,100	S	*	2/2018	Govindan Sankar Selvan	D14/485
D816,689	S		5/2018	Chalker et al.	
D817,977	S		5/2018	Kato et al.	
D832,865	S		11/2018	Dieken et al.	
D833,461	S		11/2018	Dieken et al.	
D835,631	S		12/2018	Yepez et al.	
D840,421	S		2/2019	Chalker et al.	
D840,427	S		2/2019	Javed et al.	
D844,633	S		4/2019	Cook	
D847,147	S	*	4/2019	Wesley	D14/485
D864,219	S		10/2019	Farnan et al.	
D864,224	S		10/2019	Subrahmaniyan et al.	
10,606,872	B1	*	3/2020	Shelton	G06F 16/24578
D900,835	S		11/2020	Burnell et al.	
2002/0193679	A1		12/2002	Malave et al.	
2003/0216621	A1		11/2003	Alpert et al.	
2008/0127052	A1		5/2008	Rostoker	
2009/0029631	A1		1/2009	Offer et al.	
2009/0147026	A1		6/2009	Buck et al.	
2009/0238597	A1		9/2009	Cao et al.	
2010/0096474	A1		4/2010	Zhang et al.	
2010/0100470	A1		4/2010	Buchanan et al.	
2012/0004947	A1		1/2012	Dombrowski et al.	
2014/0028682	A1		1/2014	Omiya	
2014/0188400	A1		7/2014	Dunn et al.	
2014/0206970	A1		7/2014	Wesley et al.	
2014/0282256	A1	*	9/2014	Fish	G06F 3/04817 715/835
2020/0327154	A1	*	10/2020	Shelton	G06F 16/24578

OTHER PUBLICATIONS

PCT International Searching Authority, International Search Report and Written Opinion dated Sep. 5, 2014 for Int'l Application No. PCT/US2014/012549, 11 pages.

Bergenstal MD, Rich, SMBG & CGM in Clinical Practice, Barbara Davis Center Keystone Conference 2012, Jul. 15, 2012, 50 pages.

Mazze, Roger S., Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis, Diabetes Technology & Therapeutics, vol. 10, No. 3, Jun. 1, 2008, pp. 149-159.

Bergenstal, Ricard M. et. al, Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Deciison Making in Diabetes: The Ambulatory Glucose Profile (AGP), Diabetes Technology & Therapeutics 15(3), https://www.researchgate.net/publication/235755545, Feb. 2013, 2 pages.

Verdeccia, Paolo et. al., Ambulatory Blood Pressure and Cardiovascular Outcome in Relation to Perceived Sleep Deprivation, http://hyper.ahajournals.org/content/49/4/777/tab-article-info, Mar. 21, 2011, 2 pages.

Designing Information Systems, 1.2 Designing Information Systems, https://saylordotorg.github.io, Mar. 26, 2011, 3 pages.

Wall St. Warrior, Technical Picture—Bearish Island Reversal Within a Bear Flag Pattern, http//traderjamie.blogspot.com/2011/09/technical-picture-bearish-island.html, Sep. 3, 2011, 2 pages.

AGP Reports I AGP Report, agpreport.org [online], dated May 25, 2017 by Wayback Machine® (but this date is disputed by Applicant), [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: http://www.agpreport.org/agp/agpreports> (Year: 2017).

First Clinical Experience with Retrospective Flash Glucose Monitoring, by Distiller et al., europepmc.org [online], published on Oct. 31, 2016, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: https://europepmc.org/article/med/27154973> (Year: 2016).

AGP CGM Report, by Carlson et al., researchgate.net [online], published on 2017-05-00, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: https://www.researchgate.net/figure/ AGP-CGM-Report-Ambulatory-Glucose-Profile-Continuous-Glucose-Monitoring-Report_fig 1_317159274> (Year: 2017).

Pgfplots: How to Fill the Area Under a Curve, by Ferenci, tex.stackexchange.com [online], published on Sep. 24, 2011, [retrieved on Jan. 28, 2021], retrieved from the Internet <URL: https://tex.stackexchange.com/questions/29359/ pgfplots-how-to-fill-the-area-under-a-curve-with-oblique-lines-hatching-as-a> (Year: 2011).

* cited by examiner

AGP Report

Name .....

MRN .....

GLUCOSE STATISTICS AND TARGETS

26 Feb 2019-10 Mar 2019	13 days
% Time CGM is Active	99.3%

Glucose Ranges	Targets (% of Readings (Time/Day))
Target Range 70–180 mg/dL	Greater than 70% (16hr 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 250 mg/dL	Less than 5% (1hr 12min)

Each 5% increase in time in range (70–180 mg/dL) is clinically beneficial.

Average Glucose	173 mg/dL
Glucose Management Indicator (GMI)	7.6%
Glucose Variability	49.5%

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES



Very High (>250 mg/dL) 20% (4h 48m)

High 23% (5h 31m)

Target Range (70–180 mg/dL) 47% (11h 17m)

Low 4% (58m)

Very Low (<54 mg/dL) 6% (1h 26m)

AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

captureAGP®

FIG. 1

AGP Report

Name

MRN

GLUCOSE STATISTICS AND TARGETS

26 Feb 2019–12 Mar 2019 — 13 days
% Time CGM is Active — 99.2%

Glucose Ranges	**Targets** [% of Readings (Time/Day)]
Target Range 70–180 mg/dL	Greater than 70% (16hr 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 250 mg/dL	Less than 5% (1hr 12min)

Each 5% increase in time in range (70–180 mg/dL) is clinically beneficial.

Average Glucose	173 mg/dL
Glucose Management Indicator (GMI)	7.6%
Glucose Variability	49.5%

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES



Very High (>250 mg/dL) 20% (4h 48m)
High 28% (6h 43m)
Target Range (70–180 mg/dL) 47% (11h 17m)
Low 4% (58m)
Very Low (<54 mg/dL) 1% (14m)

AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



DAILY GLUCOSE PROFILES



Each daily profile represents a midnight-to-midnight period.

captureAGP®

FIG. 2